25 Jun 2019 Cellular Logistics announces publication in Nature Communications
MADISON, Wis., June 25, 2019 – Cellular Logistics today announced the publication of an article in Nature Communications that details of a cell-production advancement with significant positive implications for the commercialization of the company’s Tandem™ technology. The article, titled Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors, appears in Nature Communications (2019) 10:2238.
The article describes the results of work by Cellular Logistics’ co-founders Eric Schmuck, Ph.D., Amish Raval, M.D., Tim Kamp, M.D., Ph.D., and others to develop a perpetual source of cells to produce the company’s Tandem™ technology. The creation of this perpetual cell source will enable the company to scale the production of its Tandem™ HF product.
Cardiac fibroblasts (CFs) play critical roles in heart development and disease. Human pluripotent stem cells (hPSCs) provide a highly renewable source for these cells, but an efficient method of producing CFs from hPSCs had not been described until publication.
The work of Drs. Schmuck, Raval, Camp and others described in the Nature Communications paper shows the differentiation of hPSCs and their generation of progenitor or precursor cells that efficiently give rise to hPSC-CFs.
The hPSC-CFs resemble native heart CFs in form and structure, growth, and production of the extracellular matrix that is the foundation of CL’s Tandem™ technology, and other important biological functions. The hPSC-CFs generated by this method provide a powerful cell source for research, drug discovery, precision medicine, and therapeutic applications in cardiac regeneration.